Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K233577
    Device Name
    Sleepio®
    Manufacturer
    Date Cleared
    2024-08-05

    (272 days)

    Product Code
    Regulation Number
    882.5801
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    Sleepio**®**

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Sleepio is a digital therapeutic intended for the treatment of chronic insomnia disorder as an adjunct to usual care in patients aged 18 and older. Sleepio is a prescription device delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) and can be made available on the order of a licensed healthcare provider.

    Device Description

    Sleepio is a digital therapeutic for the treatment of chronic insomnia / insomnia disorder. Sleepio treats chronic insomnia disorder by delivering evidence-based techniques targeting the cognitive and behavioral factors that maintain insomnia and chronic sleep problems. Patient experience is tailored based on symptoms and daily sleep tracking. In addition to core therapeutic components, there is in-the-moment therapeutic content for help falling asleep. Content is delivered via smartphone and tablet applications (iOS and Android), as well as via web. Sleepio is intended as an adjunct to usual care treatment for chronic insomnia / insomnia disorder by a healthcare provider. Healthcare providers have access to a dashboard to track patient engagement with Sleepio.

    AI/ML Overview

    Based on the provided text, the device in question is Sleepio, a digital therapeutic for the treatment of chronic insomnia disorder. Here's a breakdown of the acceptance criteria and the study proving the device meets them:

    Disclaimer: The provided document is an FDA 510(k) summary, which focuses on demonstrating substantial equivalence to a predicate device rather than setting explicit acceptance criteria for this specific device's performance in a new, de novo fashion. The clinical data presented serves to support the substantial equivalence claim by showing similar or superior performance to standard care (Sleep Hygiene Education, SHE) and implicitly, to the predicate. Therefore, the "acceptance criteria" table below is inferred from the goals of the clinical study and the claims made about the device's efficacy in the context of demonstrating substantial equivalence for an FDA 510(k) submission.

    1. Table of inferred acceptance criteria and the reported device performance

    Acceptance Criteria Category (Inferred)Specific Criterion (Inferred from study outcomes)Reported Device Performance and Comparison (Sleepio vs. SHE)
    Primary Endpoints (Co-Primary)
    Insomnia Severity Index (ISI) ImprovementSignificant reduction in ISI score compared to control (SHE).Week 10: Sleepio ISI was 12.11 (SD 6.10) vs SHE ISI 14.74 (SD 5.00). Adjusted difference: -2.37 (SE 0.56) (99% CI: -3.81, -0.92), p
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1